Ali Bessissow, MD, FRCPC: Boston Scientific: Speaker/Honoraria (Ongoing); CHESS Medical Patent: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Cook Medical: Speaker/Honoraria (Ongoing)
Lana A. Castellucci, MD, FRCPC, MSc: Amag Pharma: Speaker/Honoraria (Ongoing); Bayer: Speaker/Honoraria (Ongoing); BMS/Pfizer: Speaker/Honoraria (Ongoing); LEO pharma: Speaker/Honoraria (Ongoing); Servier: Speaker/Honoraria (Ongoing); The Academy for Continued Advancement in Healthcare Education: Speaker/Honoraria (Ongoing); Valeo: Speaker/Honoraria (Ongoing)
Samier Kamar, PharmD, RPh: CIBC: Speaker/Honoraria (Ongoing); Pear Health: Speaker/Honoraria (Ongoing); Pfizer Canada: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pharmacy Technician Professional Development Conferences: Speaker/Honoraria (Ongoing); Pharmacy U Conferences: Speaker/Honoraria (Ongoing); Thrombosis Canada: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)
Learning Objectives / Objectifs d'apprentissage:
At the end of this session participants will be able to / Au terme de cette conférence, vous serez:
describe interventional procedures for limb compromising DVT and high-risk PE such as catheter directed thrombolysis +/- IVC filter insertion +/- venous stenting;
discuss potential indications and clinical data on their efficacy and risks; and
reflect on the impact of critical illness and ICU stays on patients and their families.
This session addresses clinical aspects limb-compromising DVT and high-risk PE, and then segues into the impact of critical illness and ICU stays on patients and their families.
Session Description: • Interventional procedures for limb compromising DVT and high-risk PE • Potential indications + Clinical data on their efficacy and risks • Patient/family perspective on experience of ICU and critical illness
